Home > Insider Trading > Neogenomics Inc

Neogenomics Inc (NEO)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
31 - 37

NeoGenomics, Inc. (NEO): Hedge Funds Are Snapping Up

During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest...

Keep Reading →

December 19th, 2018 - Hedge Funds News

Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Jana Partners, Verrica Pharmaceuticals Inc (VRCA), Easterly Acquisition Corp (EACQ), Progressive Corp (PGR), and More

Billionaire Steve Cohen sees the U.S. economy slowing and predicted a bear market is coming as early as 18 months from now, according to a report by the Financial Times on Wednesday.

Keep Reading →

November 14th, 2018 - Hedge Funds Insider Trading

Is NeoGenomics, Inc. (NEO) A Good Stock To Buy?

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30.

Keep Reading →

December 9th, 2016 - Hedge Funds News

Do Hedge Funds Love NeoGenomics, Inc. (NEO)?

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small...

Keep Reading →

December 11th, 2015 - Hedge Funds News

What Sparked the Large Moves of These Five Stocks?

It's Wednesday, and shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Concordia Healthcare Corp (NASDAQ:CXRX), SanDisk Corporation (NASDAQ:SNDK), NeoGenomics, Inc.

Keep Reading →

October 21st, 2015 - Market Movers News

Carl Wiese’s Grow Partners Top Picks in Q4

Carl Wiese founded Grow Partners in 2012. Wiese has more than 22 years of investment management experience.

Keep Reading →

February 20th, 2014 - Hedge Funds News

Trius Therapeutics, Inc. (TSRX): Are Hedge Funds Right About This Stock?

Trius Therapeutics, Inc. (NASDAQ:TSRX) was in 8 hedge funds' portfolio at the end of December. TSRX has experienced a decrease in enthusiasm from smart money recently.

Keep Reading →

April 13th, 2013 - News